NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The...
Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing...
iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.https://www.angelmd.co/en/startups/ivizz
